Navigation Links
Stonegate Report About Unigene Laboratories Inc.
Date:3/13/2008

izes UGNE's manufacturing process. A positive outcome in either of these trials could catapult sCT to blockbuster status.

- UGNE's oral sCT program is progressing favorably - Apart from Novartis, Unigene is developing its own version of oral sCT utilizing tablets in an improved solid dosage form (patent applied for by the Company). The Company just announced the initiation of a Phase I/II trial, with dosing to be completed by the end of February 2008. Given the favorable market opportunities surrounding an oral sCT product, we anticipate the announcement of a partnership during the first half of 2008.

- Strong positive momentum - For the quarter ended September 30, 2007, revenues rose by 34% sequentially, reflecting a 71% increase in sales and royalties relating to Fortical(R). UGNE exhibited positive operating income for the third quarter and positive cash flow from operations for the nine months ended September 30, 2007. The cash balance grew significantly during the nine-month period, increasing by over $3.6 million to over $7 million.

- Valuation - With Fortical's imminent dominance in its market, an advancing pipeline targeting large markets, a dramatically improved financial position, and huge upside potential, we believe Unigene represents a compelling risk/reward opportunity.

Investment Summary

The commercialization of peptide-based therapeutics has been hindered by various technical challenges, and peptides have historically taken a backseat to small molecules as active pharmaceutical ingredients (APIs) for drug therapies. The advent of recombinant technology and recombinant protein production in therapeutics has facilitated the development of novel delivery systems and opened the door to new commercial opportunities for peptide-based therapies. According to Frost and Sullivan, peptides are poised to become "the products of the future", and the market for peptide-based active pharmaceutical ingredients is expected to grow
'/>"/>

SOURCE Unigene Laboratories Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
2. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
3. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
4. Helix BioPharma reports Q2 2008 highlights, financial results
5. Oncothyreon reports full year and fourth quarter 2007 financial results
6. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
7. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
8. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
9. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
11. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... St. Louis, MO (PRWEB) August 21, 2014 ... premier, full service biopharmaceutical contract development and manufacturing ... selected by Progenics Pharmaceuticals, Inc., an oncology company ... targeting and treating cancer, to manufacture the anti-prostate ... Progenics’ PSMA ADC product candidate. Under the ...
(Date:8/20/2014)... inventions licensed to biotechnology firms has revealed early ... these roadblocks, the researchers suggest that better communication ... could lead to faster commercialization down the road. ... made in university laboratories and licensed to biotechnology ... which have a high failure rate. But a ...
(Date:8/20/2014)... 20, 2014 High performance computing ... the most complete climate and Earth system model ... change issues. , Eight national laboratories, including ... National Center for Atmospheric Research, four academic institutions ... Other participating national laboratories include Argonne, Brookhaven, Lawrence ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
... Sept. 16 Martek Biosciences (Nasdaq: MATK ) today ... Directors. , , Mr. Pernock brings ... products, having served from 1994 to 2009 in a variety of ... companies. In his most recent executive role, Mr. Pernock served as ...
... , HEIDELBERG, Germany, September 16 ... Proteomics Approach Identifies new,Potential Drug Targets in Wnt Pathway , ... "Tankyrase inhibition,stabilizes axin and antagonizes Wnt signalling"** is now available ... how Cellzome,s quantitative chemical proteomics,platform was used to identify a ...
... , , SAN ... ) announced today that Kevin Gorman, President and Chief Executive Officer ... Sciences Conference in New York. , , ... p.m. Eastern Time (ET)/10:00 a.m. Pacific Time (PT). The presentation ...
Cached Biology Technology:Martek Announces Addition to Its Board of Directors 2Cellzome Technology Used to Unravel Novel Regulatory Mechanism in Cancer Signaling Pathway 2
(Date:8/20/2014)... honeybees grows to about 4,000 members, it triggers an ... of a special type of comb used for rearing ... the Department of Neurobiology and Behaviour at Cornell University, ... cycle of honeybee colonies. The results are published in ... . , Reproduction isn,t always a honeybee colony,s ...
(Date:8/19/2014)... decrease China,s increasing caesarean section rate, suggests a new ... International Journal of Obstetrics and Gynaecology (BJOG) . , ... in the world. Of 16 million babies born in ... rate is not known, the current Chinese language literature ... ranging from 36% to 58%. However, before the 1980s, ...
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s ... Meet the Philippine tarsier: a tiny, adorable and downright "cool" ... animals that Americans are familiar with," said Rafe Brown, curator-in-charge ... giant eyes and ears; an extremely cute, furry body; a ... interesting expanded fingers and toe tips that look a bit ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3
... University may make a difference one day at the gas ... organic compound on earth, has enough energy to be the ... break it down could be devised. Cellulose is a cell ... assistant professor in Kansas State University,s Division of Biology, has ...
... available in Spanish . Hake is ... and, nevertheless, resists stock depletion relatively well. At times nature ... Nerea Goikoetxea, a researcher at Azti-Tecnalia, has been witness to ... European hake population, observing which environment has favoured the species ...
... While highly potent embryonic stem cells are often the subject of ... we age, our stem cells are less pliant and less able ... breakthrough treatments for disease. An exception to this can be ... lines the inside of our mouths. These cells do not seem ...
Cached Biology News:Learning secrets of world's most common organic compound driving research for biofuels 2Hake population has withstood overfishing, thanks to the warming of the sea 2Hake population has withstood overfishing, thanks to the warming of the sea 3'Open wide' for new stem cell potential 2'Open wide' for new stem cell potential 3
cDNA Size Fractionation Columns offer an efficient and convenient method for size-fractioning double-stranded cDNA....
... delivery of buffer and fixative results ... version. In Vivo Manual Perfusion Fixation ... of buffer and fixative results in ... use and clean--Complete system with everything ...
... your 35mm dish without transferring to ... has separate openings for solution inflow ... of the liquid level in the ... entering the chamber. An adjustable metal ...
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
Biology Products: